home / stock / crdf / crdf news

CRDF News and Press, Cardiff Oncology Inc. From 09/29/20

Stock Information
Company Name: Cardiff Oncology Inc.
Stock Symbol: CRDF
Market: NASDAQ
Website: cardiffoncology.com
Menu
CRDF CRDF Quote CRDF Short CRDF News CRDF Articles CRDF Message Board
Get CRDF Alerts

News, Short Squeeze, Breakout and More Instantly...
CRDF - BTU, AHT, CRDF and USEG among midday movers

Gainers: Houston American Energy (HUSA) +245%.U.S. Energy (USEG) +167%.Greenpro Capital (GRNQ) +39%.Adial Pharmaceuticals (ADIL) +34%.Innodata (INOD) +33%.Digimarc (DMRC) +30%.VOC Energy Trust (VOC) +26%.New Concept Energy (GBR) +26%.Cardiff Oncology (CRDF) +22%.Novus Capital (...
CRDF - NanoVibronix, AIM ImmunoTech leads healthcare gainers, Vaccinex, BioSig Technologies among major losers

Gainers: NanoVibronix (NAOV) +98%, AIM ImmunoTech (AIM) +29%, Rockwell Medical (RMTI) +22%, Aurora Cannabis (ACB) +16%, Allied Healthcare Products (AHPI) +15%.Losers: Vaccinex (VCNX) -56%, BioSig Technologies (BSGM) -30%, ADC Therape...

CRDF - ROKU, ACRX, UEC and PIRS among midday movers

Gainers: Cubic (CUB) +30%.AcelRx Pharmaceuticals (ACRX) +23%.VerifyMe (VRME) +22%.Cardiff Oncology (CRDF) +19%.Roku (ROKU) +16%.Trinity Place (TPHS) +14%.Super League Gaming (SLGG) +12%.Humanigen (HGEN) +12%.CleanSpark (CLSK) +12%.MicroVision (MVIS) +11%.Losers: Condor Hospitality T...

CRDF - AcelRx Pharmaceuticals, Cardiff Oncology leads healthcare gainers, iCAD, Pieris Pharmaceuticals among major losers

Gainers: AcelRx Pharmaceuticals (ACRX) +17%, Cardiff Oncology (CRDF) +16%, Humanigen (HGEN) +14%, Medicenna Therapeutics (MDNA) +11%, Orgenesis (ORGS) +7%.Losers: iCAD (ICAD) -21%, Pieris Pharmaceuticals (PIRS) -19%, Legend Biot...
CRDF - SRNE, CRDF, INO and PLAY among midday movers

Gainers:  Ebang International (NASDAQ: EBON ) +42% . More news on: Ebang International Holdings Inc., Cardiff Oncology, Inc., Herman Miller, Inc., Stocks on the move, , Read more ...

CRDF - Cardiff Oncology's onvansertib shows sustained clinical benefit in colorectal cancer

Cardiff Oncology rises ( CRDF +24.4% ) on clinical data that further demonstrates the safety, efficacy and durability of response of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC). Data were presented at the European Society of Medical Oncology Virtual Congress . M...

CRDF - Cardiff Oncology Presents Data at ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

SAN DIEGO , Sept. 17, 2020 /PRNewswire/ --  Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-res...
CRDF - Cardiff Oncology +1% on KOL event on September 23

Cardiff Oncology (NASDAQ: CRDF )   +1% to host a key opinion leader (KOL) call focused on KRAS-mutated colorectal cancer and highlighting data from its onvansertib Phase 1b/2 clinical trial, on September 23 at 11 am-12:30 pm EDT. More news on: Cardiff Oncology, Inc., Healthcare st...

CRDF - Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial

SAN DIEGO , Sept. 15, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, today announced that it will host a key opinion leader (KO...

CRDF - Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients

SAN DIEGO , Sept. 14, 2020 /PRNewswire/ --  Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-res...
Previous 10 Next 10